Pub Date : 2022-02-28DOI: 10.47363/jonrr/2022(3)157
Omar Lazrek, M. Boufettal
{"title":"Dermatofibrosarcoma Protuberans Hight Malignity Evolving In 2 Months with Pulmonary Metastasis","authors":"Omar Lazrek, M. Boufettal","doi":"10.47363/jonrr/2022(3)157","DOIUrl":"https://doi.org/10.47363/jonrr/2022(3)157","url":null,"abstract":"","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121107285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-28DOI: 10.47363/jonrr/2022(3)158
Jamal A Khan, M. Deswal
Cancer is the second leading cause of death and continues to grow globally, exerting tremendous physical, emotional and financial strain on individuals and their families. Glioblastoma is the most frequent malignant tumor of the Central nervous system with the worst prognosis. The current conventional treatment of surgery chemo and radiation does not provide complete remission. Dendritic cells (DCs) are the most powerful antigen presenting cells and DC-based vaccination has the potential to target and eliminate GBM cells and enhance the responses of these cells to the existing therapies with minimal damage to the healthy tissues around them. It can enhance recognition of GBM cells by the patients’ immune system and activate vast, potent, and longlasting immune reactions to eliminate them. Dendritic cell immunotherapy aims at inducing an antitumoral immune response seeking to exploit this pivotal role of DC therapeutically. Keeping this in mind, a retrospective study was conducted to evaluate the safety and efficacy of dendritic cell immunotherapy in GBM patients who had recurrence or residual disease post conventional therapy. The outcome of the study has been encouraging proving beneficial for patients with minimum residual tumor burden.
{"title":"A study to Evaluate the Efficacy of Dendritic Cell Immunotherapy in Glioblastoma Multiforme","authors":"Jamal A Khan, M. Deswal","doi":"10.47363/jonrr/2022(3)158","DOIUrl":"https://doi.org/10.47363/jonrr/2022(3)158","url":null,"abstract":"Cancer is the second leading cause of death and continues to grow globally, exerting tremendous physical, emotional and financial strain on individuals and their families. Glioblastoma is the most frequent malignant tumor of the Central nervous system with the worst prognosis. The current conventional treatment of surgery chemo and radiation does not provide complete remission. Dendritic cells (DCs) are the most powerful antigen presenting cells and DC-based vaccination has the potential to target and eliminate GBM cells and enhance the responses of these cells to the existing therapies with minimal damage to the healthy tissues around them. It can enhance recognition of GBM cells by the patients’ immune system and activate vast, potent, and longlasting immune reactions to eliminate them. Dendritic cell immunotherapy aims at inducing an antitumoral immune response seeking to exploit this pivotal role of DC therapeutically. Keeping this in mind, a retrospective study was conducted to evaluate the safety and efficacy of dendritic cell immunotherapy in GBM patients who had recurrence or residual disease post conventional therapy. The outcome of the study has been encouraging proving beneficial for patients with minimum residual tumor burden.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127781401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-30DOI: 10.47363/jonrr/2021(2)153
K. Badache
This work is based on the study of patients treated for medulloblastoma metastasis at diagnosis between January 2006 and December 2015 in the neurosurgery department of the Ait IDDIR Health Hospital Establishment. Our series consisted of 16 patients, 11 men and 5 women; the median age was 16.9 years. The baseline, presentation of symptoms and signs, imaging results (MRI), surgical results and clinical results were recorded. The clinical manifestation was revealed by intracranial hypertension syndrome (100%), associated with cerebellar syndrome (80%). The localization was in Intra-nevraxics: (81.25%) and in Extra-nevraxics (18.75%). 68.75% of patients underwent total surgical excision and 31.25% underwent subtotal surgical excision. The presence of malignant cells in the CSF is marked in 56.25%. The pathological study revealed that 62.5% of cases had a classic variant and 37.5% a desmoplastic variant. 30% of the cases were classified as “standard risk” and 70% as “high risk”. The surgery was supplemented by radiotherapy of the entire neuraxis using the “movable junctions” technique in all cases. The average delay was 70 days. Adjuvant chemotherapy was performed in 9 cases. The long-term survival rate after metastasis varies between 06 months to 24 months, only 04 cases (25%) are still alive. The management of medulloblastoma must be multidisciplinary involving neurosurgeons and radiotherapist oncologists. This collaboration is the only guarantee of an improvement in his prognosis
{"title":"Management of Medulloblastoma Metastases: Algerian Experience","authors":"K. Badache","doi":"10.47363/jonrr/2021(2)153","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)153","url":null,"abstract":"This work is based on the study of patients treated for medulloblastoma metastasis at diagnosis between January 2006 and December 2015 in the neurosurgery department of the Ait IDDIR Health Hospital Establishment. Our series consisted of 16 patients, 11 men and 5 women; the median age was 16.9 years. The baseline, presentation of symptoms and signs, imaging results (MRI), surgical results and clinical results were recorded. The clinical manifestation was revealed by intracranial hypertension syndrome (100%), associated with cerebellar syndrome (80%). The localization was in Intra-nevraxics: (81.25%) and in Extra-nevraxics (18.75%). 68.75% of patients underwent total surgical excision and 31.25% underwent subtotal surgical excision. The presence of malignant cells in the CSF is marked in 56.25%. The pathological study revealed that 62.5% of cases had a classic variant and 37.5% a desmoplastic variant. 30% of the cases were classified as “standard risk” and 70% as “high risk”. The surgery was supplemented by radiotherapy of the entire neuraxis using the “movable junctions” technique in all cases. The average delay was 70 days. Adjuvant chemotherapy was performed in 9 cases. The long-term survival rate after metastasis varies between 06 months to 24 months, only 04 cases (25%) are still alive. The management of medulloblastoma must be multidisciplinary involving neurosurgeons and radiotherapist oncologists. This collaboration is the only guarantee of an improvement in his prognosis","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127676130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-30DOI: 10.47363/jonrr/2021(2)151
M. nezami
It is expected that half of the population in the US by 2045 are expected to be non Hispanic white, per US census Bureau projections.
根据美国人口普查局的预测，预计到2045年，美国一半的人口将是非西班牙裔白人。
{"title":"A Review of Disparities in Oncology Care for Patients with Limited Access and Minorities, in an Oncology Setting, an Unmet Need for this Group of Patients to Experimental Therapies","authors":"M. nezami","doi":"10.47363/jonrr/2021(2)151","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)151","url":null,"abstract":"It is expected that half of the population in the US by 2045 are expected to be non Hispanic white, per US census Bureau projections.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131423955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-31DOI: 10.47363/jonrr/2021(2)147
Rashmi R Sharma
Mental health disorders effect thinking, behave, mood etc. these can be schizophrenia, eating beh. Addictive beh, Depression, anxiety, feeling sad, down, fear, worry, guilt, anger, violence & suicidal thinking. Convolvulus is traditionally used to treat mental disorders insomnia, fatigue, low Energy
{"title":"Anticancer, Anxiolytic, Nootropic Effects of Convolvulus Pluricaulis","authors":"Rashmi R Sharma","doi":"10.47363/jonrr/2021(2)147","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)147","url":null,"abstract":"Mental health disorders effect thinking, behave, mood etc. these can be schizophrenia, eating beh. Addictive beh, Depression, anxiety, feeling sad, down, fear, worry, guilt, anger, violence & suicidal thinking. Convolvulus is traditionally used to treat mental disorders insomnia, fatigue, low Energy","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"85 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124436996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-31DOI: 10.47363/jonrr/2021(2)148
A. Kuchkuntla
Basal cell carcinoma (BCC) is the most common cancer worldwide with an estimated annual incidence of 2 million in the United States. Majority of the patients present with a suspicious skin lesion with surrounding soft tissue destruction, but distant metastasis is rare, reportedly in less than 0.05-0.1% of all cases. So far, around 350 cases have been reported with majority of metastases occurring in primary lesions of head and neck. Here, we present a patient with high-risk BCC lesion presenting with distant metastasis.
{"title":"Metastatic Basal Cell Carcinoma","authors":"A. Kuchkuntla","doi":"10.47363/jonrr/2021(2)148","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)148","url":null,"abstract":"Basal cell carcinoma (BCC) is the most common cancer worldwide with an estimated annual incidence of 2 million in the United States. Majority of the patients present with a suspicious skin lesion with surrounding soft tissue destruction, but distant metastasis is rare, reportedly in less than 0.05-0.1% of all cases. So far, around 350 cases have been reported with majority of metastases occurring in primary lesions of head and neck. Here, we present a patient with high-risk BCC lesion presenting with distant metastasis.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128922921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-31DOI: 10.47363/jonrr/2021(2)146
Manal Alnaimi, Y. Alqahtani
Hamartomas constitute a small portion of all pulmonary neoplasms. Here we present a case which was found incidentally on CT scan of the abdomen, a rare case of a giant pulmonary hamartoma (PH) was identified in the lower lobe of the left lung. The patient underwent a left exploratory thoracotomy and left lower lobectomy and the lesion was removed and identified as a chondroid hamartoma. The patient recovered successfully and obtained a repeated CT scan in 3 months, which showed no residual disease or recurrence
{"title":"Incidental Benign Giant Pulmonary Chondroid Hamartoma","authors":"Manal Alnaimi, Y. Alqahtani","doi":"10.47363/jonrr/2021(2)146","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)146","url":null,"abstract":"Hamartomas constitute a small portion of all pulmonary neoplasms. Here we present a case which was found incidentally on CT scan of the abdomen, a rare case of a giant pulmonary hamartoma (PH) was identified in the lower lobe of the left lung. The patient underwent a left exploratory thoracotomy and left lower lobectomy and the lesion was removed and identified as a chondroid hamartoma. The patient recovered successfully and obtained a repeated CT scan in 3 months, which showed no residual disease or recurrence","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122209984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-31DOI: 10.47363/jonrr/2021(2)144
Madeeha Subhan Waleed
Multiple myeloma (MM), as defined by a clonal plasma cell proliferation, manifests as end organ damage caused by the abnormally high monoclonal paraprotein.In this article, we have reviewed the potential benefits of Bispecific antibodies (BsAbs) in MM patients. In addition, new BsAbs developments and clinical trials for various MM targets are discussed in detail. Bispecific antibodies are the types of antibodies that have two different antigen binding sites in one molecule. There are 100 different classes of BsAb and all these can be divided into 2 main categories based on their fragments and both categories are under trials for MM.Despite some studies showing adverse effects development of these new treatments is going to greatly contribute to improve outcomes for a wide group of patients which also requires further clinical studies to be conducted with focus on demonstration of efficacy and safety profile.
{"title":"Role of Bispecific antibody for Multiple Myeloma; A literature Review","authors":"Madeeha Subhan Waleed","doi":"10.47363/jonrr/2021(2)144","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)144","url":null,"abstract":"Multiple myeloma (MM), as defined by a clonal plasma cell proliferation, manifests as end organ damage caused by the abnormally high monoclonal paraprotein.In this article, we have reviewed the potential benefits of Bispecific antibodies (BsAbs) in MM patients. In addition, new BsAbs developments and clinical trials for various MM targets are discussed in detail. Bispecific antibodies are the types of antibodies that have two different antigen binding sites in one molecule. There are 100 different classes of BsAb and all these can be divided into 2 main categories based on their fragments and both categories are under trials for MM.Despite some studies showing adverse effects development of these new treatments is going to greatly contribute to improve outcomes for a wide group of patients which also requires further clinical studies to be conducted with focus on demonstration of efficacy and safety profile.","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"167 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122288859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-30DOI: 10.47363/jonrr/2021(2)130
A. Kuchkuntla, Husam Hafzah, S. Desai
{"title":"Necrotizing Fasciitis after Wisdom Tooth Removal","authors":"A. Kuchkuntla, Husam Hafzah, S. Desai","doi":"10.47363/jonrr/2021(2)130","DOIUrl":"https://doi.org/10.47363/jonrr/2021(2)130","url":null,"abstract":"","PeriodicalId":351114,"journal":{"name":"Journal of Oncology Research Review & Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115306460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：